Roger Crystal has been the CEO of Opiant Pharmaceuticals Inc (NASDAQ:OPNT) since 2009. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth that the business demonstrates. And finally we will reflect on how common stockholders have fared in the last few years, as a secondary measure of performance. This process should give us an idea about how appropriately the CEO is paid.
How Does Roger Crystal’s Compensation Compare With Similar Sized Companies?
Our data indicates that Opiant Pharmaceuticals Inc is worth US$59m, and total annual CEO compensation is US$790k. That’s actually a decrease on the year before. We examined a group of similar sized companies, with market capitalizations of below US$200m. The median CEO compensation in that group is US$292k.
As you can see, Roger Crystal is paid more than the median CEO pay at companies of a similar size, in the same market. However, this does not necessarily mean Opiant Pharmaceuticals Inc is paying too much. We can better assess whether the pay is overly generous by looking into the underlying business performance.
You can see, below, how CEO compensation at Opiant Pharmaceuticals has changed over time.
Is Opiant Pharmaceuticals Inc Growing?
On average over the last three years, Opiant Pharmaceuticals Inc has grown earnings per share (EPS) by 68% each year. Its revenue is up 90% over last year.
This demonstrates that the company has been improving recently. A good result. The combination of strong revenue growth with medium-term earnings per share improvement certainly points to the kind of growth I like to see.
It could be important to check this free visual depiction of what analysts expect for the future.
Has Opiant Pharmaceuticals Inc Been A Good Investment?
I think that the total shareholder return of 52%, over three years, would leave most Opiant Pharmaceuticals Inc shareholders smiling. So they may not be at all concerned if the CEO is paid more than is normal for companies around the same size.
We compared the total CEO remuneration paid by Opiant Pharmaceuticals Inc, and compared it to remuneration at a group of similar sized companies. We found that it pays well over the median amount paid in the benchmark group.
However, the earnings per share growth over three years is certainly impressive. On top of that, in the same period, returns to shareholders have been great. Considering this fine result for shareholders, we daresay the CEO compensation might be apt.
Or you might rather take a peek at this analytical visualization of historic cash flow, earnings and revenue.
To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at firstname.lastname@example.org.